[
  {
    "ts": "2025-10-11T00:27:00+00:00",
    "headline": "AstraZeneca Cuts Discounted Drug Pricing Deal With the White House. The Stock Is Rising.",
    "summary": "AstraZeneca  on Friday became the second big drugmaker after  Pfizer  to cut a pricing deal with the White House, announcing an agreement alongside President Donald Trump at a late afternoon press conference.  AstraZeneca stock was up 1.6% in Friday after-hours trading.  AstraZeneca, which is headquartered in the United Kingdom but earned 43% of its revenues in the U.S. in 2024, committed to offer all of its prescription medications to Medicaid at “most favored nation prices”, which means “the lowest price anywhere in the world,” said Trump.",
    "url": "https://www.barrons.com/articles/astrazeneca-trump-deal-pfizer-a13f60fe?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "f43b8c13-3e25-3db2-bd66-4b3799109936",
      "content": {
        "id": "f43b8c13-3e25-3db2-bd66-4b3799109936",
        "contentType": "STORY",
        "title": "AstraZeneca Cuts Discounted Drug Pricing Deal With the White House. The Stock Is Rising.",
        "description": "",
        "summary": "AstraZeneca  on Friday became the second big drugmaker after  Pfizer  to cut a pricing deal with the White House, announcing an agreement alongside President Donald Trump at a late afternoon press conference.  AstraZeneca stock was up 1.6% in Friday after-hours trading.  AstraZeneca, which is headquartered in the United Kingdom but earned 43% of its revenues in the U.S. in 2024, committed to offer all of its prescription medications to Medicaid at “most favored nation prices”, which means “the lowest price anywhere in the world,” said Trump.",
        "pubDate": "2025-10-11T00:27:00Z",
        "displayTime": "2025-10-11T00:27:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f43b8c13-3e25-3db2-bd66-4b3799109936/astrazeneca-cuts-discounted.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/064b25b7f19b4bc17c65f72396d63020",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EzcVEHQpW60J5oZ.Xkybiw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/064b25b7f19b4bc17c65f72396d63020.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/z5RSLgiQiLEaVUw8Q_DdeQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/064b25b7f19b4bc17c65f72396d63020.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/astrazeneca-trump-deal-pfizer-a13f60fe?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-11T00:18:00+00:00",
    "headline": "Biotech Stocks Have Struggled Since 2021. Why They’re Coming Back.",
    "summary": "Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswing.",
    "url": "https://www.barrons.com/articles/biotech-stocks-have-struggled-since-2021-why-theyre-coming-back-9d708db9?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "8f1bb26f-1684-36f6-b075-d390f064c700",
      "content": {
        "id": "8f1bb26f-1684-36f6-b075-d390f064c700",
        "contentType": "STORY",
        "title": "Biotech Stocks Have Struggled Since 2021. Why They’re Coming Back.",
        "description": "",
        "summary": "Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswing.",
        "pubDate": "2025-10-11T00:18:00Z",
        "displayTime": "2025-10-11T00:18:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8f1bb26f-1684-36f6-b075-d390f064c700/biotech-stocks-have-struggled.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/5d0dd331e636e0ef6df76c4bfc445000",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QQ1pExlmVXCHwh6o4cycPw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/5d0dd331e636e0ef6df76c4bfc445000.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.uBeRFvbAgrcHVmqz_afng--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/5d0dd331e636e0ef6df76c4bfc445000.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/biotech-stocks-have-struggled-since-2021-why-theyre-coming-back-9d708db9?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PLD"
            },
            {
              "symbol": "PLDGP"
            },
            {
              "symbol": "ABT"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]